StockNews.AI
ARMP
StockNews.AI
1 min

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

1. Armata's cGMP facility in Los Angeles starts production for phage-based therapeutics. 2. FDA has been notified of the facility's operational readiness with no issues reported. 3. The facility enables Armata to progress toward pivotal Phase 3 trials planned for 2026. 4. Focus on domestic manufacturing aligns with federal efforts to support essential medicine supply. 5. Armata develops therapies for antibiotic-resistant infections, indicating high market potential.

7m saved
Insight
Article

FAQ

Why Bullish?

The commissioning of the manufacturing facility demarcates progress for Armata's operational capabilities. Similar biotech company milestones often lead to increased investor confidence and stock price appreciation.

How important is it?

The news highlights technological and operational advancements critical for Armata's product pipeline, making it a significant influence on future revenue generation and stock performance.

Why Long Term?

The full implications of the facility's operational capabilities will manifest as clinical trials progress and regulatory milestones are achieved, likely influencing investor sentiment and stock valuation over time.

Related Companies

SNYPFEMRNABIIBGSK
, /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its state-of-the-art current Good Manufacturing Practice ("cGMP") manufacturing facility in Los Angeles, California, has been formally commissioned. As part of the commissioning process, the U.S. Food and Drug Administration (the "FDA") has been notified that production has commenced, and full production runs have been completed with no issues or concerns. "The full commissioning of our state-of-the-art manufacturing facility in Los Angeles represents a key milestone for Armata, ensuring that we are operationally ready to initiate pivotal studies of our phage-based therapeutics," stated Dr. Deborah Birx, Chief Executive Officer of Armata. "Importantly, this facility reflects our commitment to onshore manufacturing, from procurement of active pharmaceutical ingredients through fill and finish activities, to ensure that we can achieve the quality, quantity, and consistency of high-purity phage that our clinical programs require, while aligning with the federal government's efforts to further secure the essential medicine supply chain through domestic manufacturing. With this production facility now online, I believe we have taken another meaningful step forward in our quest to ensure that our phage-based therapeutics are available to treat patients in need in the not-too-distant future and reduce reliance on antibiotics that continues to contribute to the antimicrobial resistance crisis." The facility, which spans 56,000 square feet, includes 10,000 square feet of cGMP clean rooms, an automated fill and finish suite, quality control laboratories for internal testing and release of clinical trial material, research and development laboratories, and administrative space. The facility allows Armata to manufacture its proprietary high-purity, multi-phage cocktails in support of the Company's future clinical trials, including advancement of AP-SA02 into a potential pivotal Phase 3 trial that Armata plans to initiate in 2026, subject to review and feedback from the FDA, as well as to support future commercial production and potential partnering and contract manufacturing opportunities.  About Armata Pharmaceuticals, Inc.Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization. Forward Looking StatementsThis communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 21, 2025, and in its subsequent filings with the SEC. Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.  Media Contacts: At Armata: Pierre Kyme[email protected]310-665-2928 Investor Relations: Joyce AllaireLifeSci Advisors, LLC[email protected]212-915-2569 SOURCE Armata Pharmaceuticals, Inc.

Related News